Cargando…
Pilocytic astrocytoma: pathology, molecular mechanisms and markers
Pilocytic astrocytomas (PAs) were recognized as a discrete clinical entity over 70 years ago. They are relatively benign (WHO grade I) and have, as a group, a 10-year survival of over 90 %. Many require merely surgical removal and only very infrequently do they progress to more malignant gliomas. Wh...
Autores principales: | Collins, V. Peter, Jones, David T. W., Giannini, Caterina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436848/ https://www.ncbi.nlm.nih.gov/pubmed/25792358 http://dx.doi.org/10.1007/s00401-015-1410-7 |
Ejemplares similares
-
MAPK pathway activation in pilocytic astrocytoma
por: Jones, David T. W., et al.
Publicado: (2011) -
Recent Progress in the Pathology and Genetics of Pilocytic and Pilomyxoid Astrocytomas
por: Ding, Cristine, et al.
Publicado: (2019) -
Adult pilocytic astrocytoma in the molecular era: a comprehensive review
por: Gregory, Timothy A, et al.
Publicado: (2021) -
Analysis of pilocytic astrocytoma by comparative genomic hybridization
por: Sanoudou, D, et al.
Publicado: (2000) -
The age of adult pilocytic astrocytoma cells
por: Voronina, Natalia, et al.
Publicado: (2021)